60 DEGREES PHARMACEUTICALS, INC. (SXTP) Stock Profile — Insider Trades & Financials

EPS$-4.65

Market Cap$4.7M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Geoffrey Dow

CEO & Executive Director

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.

Founded: 2010
Employees: 3

⚡

Core Efficiency

D/E Ratio?

0.57

📊

Profitability Ratios

Current Ratio?

2.66

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 29, 2026 (in 142 days)

Annual Report (10-K) — Estimated

Aug 29, 2026

Predicted10-K

Mar 30, 2026

10-KQ4 20250d after period end

Nov 13, 2025

10-QQ3 20250d after period end

Aug 13, 2025

10-QQ2 20250d after period end

May 15, 2025

10-QQ1 20250d after period end

Mar 27, 2025

10-KQ4 20240d after period end

Nov 14, 2024

10-QQ3 20240d after period end

Aug 14, 2024

10-QQ2 20240d after period end

May 15, 2024

10-QQ1 20240d after period end

Loading company sections...

60 DEGREES PHARMACEUTICALS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness